EpiPharma – From Cutting Edge Synthesis Technologies to Complete Preclinical Characterization

Authors

  • István Mándity Epipharma Drug Development LLC., Szőregi Str. 38., H-6726 Szeged, Hungary; Semmelweis University, Högyes Endre Str.7., H-1092, Budapest, Hungary; Research Center for Natural Sciences, Magyar Tudósok krt. 2., H-1117, Budapest Hungary
  • József Maléth Epipharma Drug Development LLC., Szőregi Str. 38., H-6726 Szeged, Hungary; University of Szeged, Dugonics sqr. 13., H-6720, Szeged, Hungary
  • Beáta Mándityné Huszka Epipharma Drug Development LLC., Szőregi Str. 38., H-6726 Szeged, Hungary; Research Center for Natural Sciences, Magyar Tudósok krt. 2., H-1117, Budapest Hungary
  • Petra Pallagi Epipharma Drug Development LLC., Szőregi Str. 38., H-6726 Szeged, Hungary; University of Szeged, Dugonics sqr. 13., H-6720, Szeged, Hungary
  • Gábor Heltovics Epipharma Drug Development LLC., Szőregi Str. 38., H-6726 Szeged, Hungary

DOI:

https://doi.org/10.33892/aph.2021.91.234-235

Keywords:

Synthesis, peptide, foldamer, ex vivo models, biomedical research

Published

2021-11-15

How to Cite

(1)
Mándity, I.; Maléth, J.; Mándityné Huszka, B.; Pallagi, P.; Heltovics, G. EpiPharma – From Cutting Edge Synthesis Technologies to Complete Preclinical Characterization. Acta Pharm Hung 2021, 91, 234-235.

Issue

Vol. 91 No. 3-4 (2021): Abstracts of DDRS 2021 Conference, November 15-17, 2021, Budapest, Hungary

Section

Short communication

Copyright (c) 2021 Acta Pharmaceutica Hungarica

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

APH is published as a diamond open-access journal under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Creative Commons License